Seòmar agus comataidhean

Following a successful three year pilot, in 2013 the four nations agreed to a 10 year grant to support those affected by the thalidomide drug. Over the last nine years the Scottish Government has issued a total of £11.512 million to the Thalidomide Trust, for distribution to Scottish survivors. A further £1.636 Million is projected for the final year (2022-23), bringing total funding to £13.15 million.

The Scottish Government receives annual funding from the UK Government as part of the Barnett consequentials, however no funding is specifically ‘ring fenced’ for Thalidomide.

Breakdown of Funding:

The Centre for Sustainable Delivery (CfSD) is working collaboratively with the Dermatology AI Consortium championing Community Local Image Centres (CLICs) to improving the capture of images as part of the dermatology pathway. The idea is relatively new and the CLIC model is still in development. The consortium will be developing the operating model and evidence base to show their benefit. CfSD awaits the outcome of this with interest.

It should be noted that the Consortium is also considering other approaches to image acquisition to support dermatology referral – most notably increasing the ease and quality of image acquisition in Primary Care. It is unlikely that a one-size-fits all will suit the varied geography of NHS Boards and therefore CfSD is working to understand the current pathway arrangements in all Boards to support image acquisition prior to Secondary Care.

In Scotland, NHS Forth Valley is hosting a national project to support early diagnosis of skin cancer supported by digitalisation, the use of high-quality images, and machine learning. The project is called 25 by 25 - diagnosing cancer within 25 minutes by 2025. Industry, academics, and NHS are collaborating to rapidly innovate to create AI solutions in skin cancer.

This work is supported through the Scottish Health Industry Partnership and linked to the Health and Social Care and Wellbeing Programme. It takes the form of a number of challenges where partners innovate to find solutions to preparing images, creating AI learning environments, and real world Test Beds to try out new approaches in primary care with Consultant Dermatologist support.

The Scottish Government is not considering the possibility of allowing Health Boards to take over the running of community pharmacies that are struggling to remain open. Community pharmacies, along with other primary care contractors, are wholly independent private entities providing NHS services on behalf the Health Board. Any challenges faced by community pharmacy contractors in delivering existing pharmaceutical care services should be discussed with the Health Boards who will be able to consider actions to support service provision.

There is a range of projects being undertaken in Scotland to explore the use of AI in further high-demand medical areas, ranging from robotic surgery to the use of virtual reality in supporting mental wellbeing is currently being researched, evaluated, and implemented in Scotland.

The Industrial Centre for Artificial Intelligence Research in Digital Diagnostics (iCAIRD) website provides more information:

iCAIRD – Industrial Centre for Artificial Intelligence Research in Digital Diagnostics .

The Scottish Government has invested in the Detect Cancer Early programme in this area, has committed to investing in an AI Hub, and has prioritised the 25 by 25 programme for innovation investment in 2022.

This will enable AI innovation in the form of AI enabled triage, diagnostics, and treatment decision making support for Clinicians.

The Scottish Government has embraced artificial intelligence (AI) as a transformational technology for public good. We were the first UK country to establish an AI Strategy which set out our ambition for Scotland to become a global exemplar in the ethical and innovative deployment of AI.

As part of the Recovery Plans for the NHS, social care and the economy, the Government will support innovation in health care delivery and the adoption of AI solutions into use. Accelerating the adoption of new technologies that support improved access to healthcare, such as the use of artificial intelligence, will be integral to the recovery of NHS services, and there are a range of partner organisations that are central to this work, including the new national Centre for Sustainable Delivery.

The Scottish Government does not provide direct funding for the NHS Centre for Integrative Care (CIC). The CIC is a facility owned, operated and funded by NHS Greater Glasgow and Clyde (NHS GGC).

It is for individual NHS Boards to decide which services they make available based on national and local priorities and the needs of their resident populations.

A clinical refresh of the Scottish Referral Guidelines for Suspected Cancer has been completed with revised guidance published in January 2019. The Guidelines support primary care clinicians in ensuring those with symptoms suspicious of cancer are put on the right pathway at the right time, including possible skin cancers.

In December 2021, the Scottish Government published a refreshed Framework for Effective Cancer Management. This Framework provides NHS Cancer Teams with the tools to effectively manage USC patients from the point of referral to first treatment to improve patient experience and cancer waiting times. Tailored support will be provided to all NHS Boards to ensure the eight key elements are embedded, where relevant, across cancer pathways and specialties, including dermatology.

The Centre for Sustainable Delivery (CfSD) is working with a number of Health Boards to implement the Digital Dermatology app, which allows patients to interact with a clinician at a time convenient to them, without having to attend hospital. This will support dermatology teams in conducting more virtual appointments. CfSD also supports a Dermatology Pathways app and website which provides clinically validated pathway information to GPs and other health professionals for many of the most common skin conditions, with the aim of supporting access for patients who most need treatment in the most appropriate care setting. As part of this, CfSD is working with the British Association of Dermatologists to increase the number of pathways covered by this approach.